secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2026-06-04T13:00:32+00:00
Accession:  0001493152-26-027209
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine to host virtual KOL event on LPCN 1154 for postpartum depression on June 12, 2026
--------------------------------------------------------------------------------

- Virtual KOL event focused on unmet needs in postpartum depression and clinical profile of LPCN 1154 (oral brexanolone).
- Event scheduled for June 12, 2026 at 11:00 AM ET; advance registration required.
- LPCN 1154 Phase 3 trial showed efficacy in subgroup analysis excluding outlier site; 100% dosing completion.
- PPD affects ~1 in 5 U.S. women; annual economic burden estimated at $14.2 billion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226027209/0001493152-26-027209-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226027209/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-027209

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer